Beta-interferons in multiple sclerosis: A single center experience in India
2010
Comment on Beta-interferons in Multiple Sclerosis
Commentary
Author Information
Author(s): Sourabh Aggarwal, Vishal Sharma, Jesna S.
Primary Institution: University College of Medical Sciences, New Delhi, India
Conclusion
Mitoxantrone is a promising and cost-effective alternative therapy for multiple sclerosis in India.
Supporting Evidence
- Mitoxantrone has shown promising results as an initial therapy for multiple sclerosis.
- New therapies like alemtuzumab and natalizumab have shown improvements in disability but are expensive.
- Mitoxantrone is better when used as induction therapy followed by glatiramer acetate.
Takeaway
This article talks about how a cheaper medicine called mitoxantrone can help people with multiple sclerosis, especially when other treatments are too expensive.
Limitations
The high cost of new therapies limits their use in treating multiple sclerosis in India.
Want to read the original?
Access the complete publication on the publisher's website